Xiaoxue Li

Also affiliated with United States Food and Drug Administration, Center for Drug Evaluation and Research, Nanjing Second Hospital

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum”.

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1270

N/A

1.2DataRank · unranked

46 citations

Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Lingshan Wang +14 more

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3439

N/A

0.470DataRank · unranked

22 citations

Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie Aungst, Amy M. Skinner +22 more

FDA Approval Summary: Vorasidenib for IDH -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1333

N/A

0DataRank · unranked

12 citations

Amy Barone, Stephanie Aungst, Claudia P. Miller, Suryatheja Ananthula, Youwei Bi +20 more